Skip to main content
GutCited

Curcumin therapy in inflammatory bowel disease: a pilot study.

Peter R Holt, Seymour Katz, Robert Kirshoff
Other Digestive diseases and sciences 2005 461 citações
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'pmid\u003D16240238'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Tipo de Estudo
Controlled Clinical Trial
Tamanho da Amostra
10
População
5 ulcerative proctitis and 5 Crohn's disease patients
Intervenção
Curcumin therapy in inflammatory bowel disease: a pilot study. Curcumin (pure preparation)
Comparador
None
Desfecho Primário
Clinical improvement in UC proctitis and Crohn's
Direção do Efeito
Positive
Risco de Viés
High

Abstract

Curcumin, a natural compound used as a food additive, has been shown to have anti-inflammatory and antioxidant properties in cell culture and animal studies. A pure curcumin preparation was administered in an open label study to five patients with ulcerative proctitis and five with Crohn's disease. All proctitis patients improved, with reductions in concomitant medications in four, and four of five Crohn's disease patients had lowered CDAI scores and sedimentation rates. This encouraging pilot study suggests the need for double-blind placebo-controlled follow-up studies.

Resumo Rápido

All proctitis patients improved, with reductions in concomitant medications in four, and four of five Crohn's disease patients had lowered CDAI scores and sedimentation rates, which suggests the need for double-blind placebo-controlled follow-up studies.

Used In Evidence Reviews

Similar Papers